Alloy Therapeutics operates in the biotech and pharmaceutical space, where the threat model isn't just external actors - it's also intellectual property leakage, adversarial manipulation of AI/ML models underpinning drug discovery workflows, and the sprawling attack surface of a multi-site, multi-national organization. Founded in 2017, the company runs an integrated drug discovery platform spanning antibodies, bispecifics, TCR mimics, genetic medicines, and cell therapies. That platform embeds AI/ML directly into discovery pipelines and sits on one of the industry's largest proprietary experimental datasets - data that is, by definition, a crown-jewel asset requiring serious protection.
The technical stack runs across sites in Waltham, MA; Athens, GA; Cambridge, UK; Basel, Switzerland; and Fujisawa, Japan. Over 100 scientists operate within this ecosystem, generating and consuming sensitive research data at scale. Security work here means defending a distributed, research-heavy environment where the boundaries between compute, data science, and wet-lab operations blur. The company's open-access, partner-first model - 100% of profits reinvested into innovation and flexible collaboration structures - means external integrations and data-sharing agreements multiply the perimeter continuously.
For security practitioners, the concrete challenge set spans securing ML pipelines and training data integrity, protecting proprietary experimental datasets across jurisdictions with varying regulatory regimes, hardening infrastructure supporting multi-modal biologics design, and managing third-party risk in a collaboration-heavy operating model. Alloy competes on therapeutic outcomes rather than exclusive platform access, which means its security posture has to support openness without compromising the core assets that make the platform valuable in the first place.
